在患有性综合征的患者中添加Dapagliflozin的临床价值
Magdy ElSharkawy1, Ahmed Emara1, Mohamed Mohyeldin Ahmed1
1Faculty of Medicine, Internal Medicine and Nephrology Department, Ain Shams University, Ramsis Street 38, Abbasia, Cairo, Postal Code: 11566, Egypt.
International urology and nephrology
|June 11, 2024
概括
像达帕格利弗洛辛这样的-葡萄糖共运输体2 (SGLT2) 抑制剂在治疗性综合征方面具有潜力. 虽然达帕格利弗洛辛没有比标准治疗更显著地减少蛋白尿,但它有助于减肥,并改善了甘油三.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在接受免疫抑制的性患者中使用-葡萄糖共运输体2 (SGLT2) 抑制剂尚未得到充分证实.
- 这项研究调查了达帕格利弗洛辛在患有初级性综合征的非糖尿病患者中的作用.
研究的目的:
- 评估达帕格利弗洛辛作为非糖尿病患者初级性综合征的辅助疗法的影响.
- 为了评估6个月治疗后蛋白尿和估计的淋巴膜过率 (eGFR) 的变化.
主要方法:
- 一项随机对照试验,涉及60名非糖尿病原发性病综合征患者.
- 患者被分配到标准护理加上10毫克达帕格利弗洛辛或单独标准护理.
- 测量结果包括6个月的蛋白尿 (UPCR) 和eGFR变化.
主要成果:
- 两组都显示出显著的蛋白尿减少,但两组之间的差异在统计上并不显著.
- 达帕格利弗洛辛最初导致eGFR的暂时下降,在6个月后,两组的eGFR都稳定.
- 在达帕格利弗洛辛组观察到体重显著减少和甘油三水平的改善.
结论:
- 附加的达帕格利弗洛辛可能会在初级瘤综合征中提供超越标准护理的好处,特别是在体重和脂质管理方面.
- 根据研究结束,蛋白尿减少在各组之间是可比的,而eGFR保持稳定.
- 需要进一步的长期研究来澄清与免疫抑制有关的影响和潜在的混因素.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:16Antihypertensive Drugs: Action of Diuretics
665
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
01:15Diabetes: Management and Pharmacotherapy
260
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
260
01:11Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84